Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lydia Scarfò

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Blood|March 2, 2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugsCandida Vitale, Chiara Salvetti, Valentina Griggio, et al.
Nature Communications|May 5, 2018
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progressionDiego Farinello, Monika Wozińska, Elisa Lenti, et al.
Haematologica|May 21, 2016
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptorsLesley-Ann Sutton, Emma Young, Panagiotis Baliakas, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Leukemia|September 11, 2024
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemiaDaniel Hägerstrand, Blaž Oder, Diego Cortese, et al.
Haematologica|September 29, 2018
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemiaPanagiotis Baliakas, Theodoros Moysiadis, Anastasia Hadzidimitriou, et al.
Blood Advances|January 25, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSilvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, et al.
British Journal of Haematology|August 15, 2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signallingRiccardo Moia, Lodovico Terzi di Bergamo, Donatella Talotta, et al.
Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.
JCO Oncology Practice|August 25, 2025
Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled TrialThomas Chatzikonstantinou, Maria Vasilopoulou, Dimitrios Kyrou, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Blood|March 2, 2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugsCandida Vitale, Chiara Salvetti, Valentina Griggio, et al.
Nature Communications|May 5, 2018
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progressionDiego Farinello, Monika Wozińska, Elisa Lenti, et al.
Haematologica|May 21, 2016
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptorsLesley-Ann Sutton, Emma Young, Panagiotis Baliakas, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Leukemia|September 11, 2024
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemiaDaniel Hägerstrand, Blaž Oder, Diego Cortese, et al.
Haematologica|September 29, 2018
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemiaPanagiotis Baliakas, Theodoros Moysiadis, Anastasia Hadzidimitriou, et al.
Blood Advances|January 25, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSilvia Bonfiglio, Lesley-Ann Sutton, Viktor Ljungström, et al.
British Journal of Haematology|August 15, 2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signallingRiccardo Moia, Lodovico Terzi di Bergamo, Donatella Talotta, et al.
Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.
JCO Oncology Practice|August 25, 2025
Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled TrialThomas Chatzikonstantinou, Maria Vasilopoulou, Dimitrios Kyrou, et al.
Pageof 12